Discover

AVXL
Anavex Life Sciences Corp.
2.58
2 x 1.86
2 x 3.31
bid
ask
-
0.01
0.39%
2 @ 04:00 PM
2.63 +0.05 (1.94%)
Ytd-27.53%
1y-72.35%
2.56
day range
2.63
2.41
52 week range
13.99
Open2.59Prev Close2.59Low2.56High2.63Mkt Cap239.09M
Vol1.12MAvg Vol1.21MEPS-0.46P/EN/AForward P/E-17.25
Beta0.60Short Ratio10.82Inst. Own32.04%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-0250-d Avg2.89200-d Avg4.731yr Est35.47

AVXL News

benzinga.com
Anavex Life Sciences Receives Expected Delinquency Notification From Nasdaq

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta

benzinga.com
Anavex Life Sciences Announces New Findings On The Shared Biology Between Autism Spectrum Disorder A

Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD)

benzinga.com
Anavex Life Sciences Continues Dialogue With EMA To Advance Development Program Of Oral Blarcamesine

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta

Crude Oil Moves Lower; Cintas Raises FY2026 Forecast
benzinga.com
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast

The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp

Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings
benzinga.com
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings

US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
benzinga.com
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback

Anavex shares fall after pulling EU filing for blarcamesine in Alzheimer's; EMA feedback prompts

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com
Anavex Withdraws EU Filing For Alzheimer's Treatment After Regulator Feedback

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta

benzinga.com
Anavex Life Sciences Presents New Data Of Blarcamesine At AD/PD 2026 Conference; Data Show Brain-Vol

Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared

Anavex Life Lead Drug Targets Early Alzheimer's Cause - New Study Highlights
benzinga.com
Anavex Life Lead Drug Targets Early Alzheimer's Cause - New Study Highlights

New study links early brain cleanup failure to Alzheimer's, supporting Anavex Life drug approach

benzinga.com
Anavex Life Sciences Announces New Study Supporting Blarcamesine As A Potential Alzheimer's Treatmen

Anavex highlighted a new peer-reviewed study published by University of California in Proceedings of

benzinga.com
Anavex Tests Parkinson's Drug That May Help Regrow Brain Cells

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta

What's Going On With Anavex Life Sciences Stock On Wednesday?
benzinga.com
What's Going On With Anavex Life Sciences Stock On Wednesday?

Anavex Life Sciences' stock rises despite no news, up over 40% this year as investors watch Alzh

benzinga.com
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $24 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an

benzinga.com
Anavex Life Sciences Q1 EPS $(0.06) Beats $(0.11) Estimate

Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.06) per share which beat the ana

Earnings Scheduled For February 9, 2026
benzinga.com
Earnings Scheduled For February 9, 2026

Anavex Life Sciences's Earnings Outlook
benzinga.com
Anavex Life Sciences's Earnings Outlook

benzinga.com
Anavex Life Sciences Joins ACCESS-AD

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), today announc

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $24 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an

benzinga.com
Anavex Life Sciences To Submit Data On Phase IIb/III ANAVEX2-73-AD-004 Alzheimer's Disease Trial To

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-st

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $24 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an

benzinga.com
Anavex Life Sciences Requests European Medicines Agency To Re-Examine Its Opinion On Blarcamesine Fo

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $24 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an

Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stoc

Top Stocks with Earnings This Week: Costco, MongoDB, Ulta and More
benzinga.com
Top Stocks with Earnings This Week: Costco, MongoDB, Ulta and More

Retail investors are prepping for a lighter week of corporate earnings featuring Costco, MongoDB, Ul

benzinga.com
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $24 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an

Earnings Scheduled For November 25, 2025
benzinga.com
Earnings Scheduled For November 25, 2025

A Preview Of Anavex Life Sciences's Earnings
benzinga.com
A Preview Of Anavex Life Sciences's Earnings

benzinga.com
HC Wainwright & Co. Maintains Buy on Anavex Life Sciences, Lowers Price Target to $20

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Anavex Life Sciences (NASDAQ:AVXL) w

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session
benzinga.com
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Fr

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an

Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
benzinga.com
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Gr

Anavex reports sustained cognitive benefits from oral blarcamesine, showing slower Alzheimer's p

Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
benzinga.com
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Gr

Anavex reports sustained cognitive benefits from oral blarcamesine, showing slower Alzheimer's p

benzinga.com
Anavex Highlights Oral Blarcamesine's Patient-Centric Alzheimer's Care At Alzheimer Europe Conferenc

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta

benzinga.com
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $42 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an

benzinga.com
Anavex Life Sciences Announces Development Of Once-Daily Oral Tablet Formulation For ANAVEX 3-71 Pro

ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both mal

benzinga.com
Anavex Schizophrenia Drug Shows Safety Results in Phase 2 Trial

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-sta

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an

benzinga.com
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $42 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an

benzinga.com
Anavex Life Sciences Highlights New Clinical Precision Medicine Population 48-Week Data

New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabili

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an

benzinga.com
HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $42 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows
benzinga.com
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New

Anavex published data showing blarcamesine prevented amyloid-related brain damage in mice, supportin

benzinga.com
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy an